Medivo Inc., a New York City-based health monitoring platform that connects doctors, consumers and clinical labs, raised a $15m Series B financing.
The round was led by the Merck Global Health Innovation Fund (GHIF), with participation from existing investors Safeguard Scientifics, Inc. (NYSE:SFE) and MentorTech Ventures.
The company, which had raised $7m in Series A financing in late 2011 (read here), intends to use the funds to expand its clinical data platform, enrich analytics services, build out connectivity to additional data sources, enhance its product offerings for physicians and consumers, and develop new patient engagement services.
Led by Sundeep Bhan, CEO and Co-Founder, Medivo provides a cloud-based, health monitoring platform that connects doctors, consumers and clinical labs making it easy to access lab tests, measure and track health information. All services—including mobile tools and simple explanations of lab results—are free for physicians and consumers.
The company’s platform (HIPAA-compliant) includes modules for physicians and patients with diabetes, dyslipidemia, hepatitis C, gout, low testosterone, irritable bowel disease, hereditary angioedema, and chronic myelogenous leukemia. Medivo is now working to expand its network of laboratories and health monitoring modules, including obesity, rheumatoid arthritis, hepatitis B, HIV, colon cancer, breast cancer, prostate cancer, myelofibrosis, multiple myeloma, growth hormone deficiency, osteoporosis, hypothyroidism, and multiple sclerosis.